Applied DNA Sciences Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $1.05
- Today's High:
- $1.13
- Open Price:
- $1.05
- 52W Low:
- $0.62
- 52W High:
- $7.35
- Prev. Close:
- $1.05
- Volume:
- 140300
Company Statistics
- Market Cap.:
- $16.26 million
- Book Value:
- 0.71
- Revenue TTM:
- $19.27 million
- Operating Margin TTM:
- -54.41%
- Gross Profit TTM:
- $5.05 million
- Profit Margin:
- -38.36%
- Return on Assets TTM:
- -41.33%
- Return on Equity TTM:
- -84.25%
Company Profile
Applied DNA Sciences Inc had its IPO on 2003-07-15 under the ticker symbol APDN.
The company operates in the Healthcare sector and Diagnostics & Research industry. Applied DNA Sciences Inc has a staff strength of 61 employees.
Stock update
Shares of Applied DNA Sciences Inc opened at $1.05 at the start of the last trading session i.e. 2023-03-19.
The stocks traded within a range of $1.05 - $1.13, and closed at $1.09.
This is a +3.81% increase from the previous day's closing price.
A total volume of 140,300 shares were traded at the close of the day’s session.
In the last one week, shares of Applied DNA Sciences Inc have slipped by -10.66%.
Applied DNA Sciences Inc's Key Ratios
Applied DNA Sciences Inc has a market cap of $16.26 million, indicating a price to book ratio of 2.6348 and a price to sales ratio of 1.0292.
In the last 12-months Applied DNA Sciences Inc’s revenue was $19.27 million with a gross profit of $5.05 million and an EBITDA of $-9173517. The EBITDA ratio measures Applied DNA Sciences Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Applied DNA Sciences Inc’s operating margin was -54.41% while its return on assets stood at -41.33% with a return of equity of -84.25%.
In Q4, Applied DNA Sciences Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 26.3%.
Applied DNA Sciences Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-0.54 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Applied DNA Sciences Inc’s profitability.
Applied DNA Sciences Inc stock is trading at a EV to sales ratio of 0.8223 and a EV to EBITDA ratio of -1.2263. Its price to sales ratio in the trailing 12-months stood at 1.0292.
Applied DNA Sciences Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $20.30 million
- Total Liabilities
- $3.33 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $20619
- Dividend Payout Ratio
- 0%
Applied DNA Sciences Inc ended 2023 with $20.30 million in total assets and $0 in total liabilities. Its intangible assets were valued at $20.30 million while shareholder equity stood at $9.16 million.
Applied DNA Sciences Inc ended 2023 with $0 in deferred long-term liabilities, $3.33 million in other current liabilities, 12909.00 in common stock, $-296343460.00 in retained earnings and $0 in goodwill. Its cash balance stood at $12.88 million and cash and short-term investments were $12.88 million. The company’s total short-term debt was $0 while long-term debt stood at $0.
Applied DNA Sciences Inc’s total current assets stands at $18.33 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $4.05 million compared to accounts payable of $2.02 million and inventory worth $477014.00.
In 2023, Applied DNA Sciences Inc's operating cash flow was $0 while its capital expenditure stood at $20619.
Comparatively, Applied DNA Sciences Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- $1.09
- 52-Week High
- $7.35
- 52-Week Low
- $0.62
- Analyst Target Price
- $4
Applied DNA Sciences Inc stock is currently trading at $1.09 per share. It touched a 52-week high of $7.35 and a 52-week low of $7.35. Analysts tracking the stock have a 12-month average target price of $4.
Its 50-day moving average was $1.49 and 200-day moving average was $1.73 The short ratio stood at 4.34 indicating a short percent outstanding of 0%.
Around 139.6% of the company’s stock are held by insiders while 1567.5% are held by institutions.
Frequently Asked Questions About Applied DNA Sciences Inc
Similar Industry Stocks (Diagnostics & Research)
Most Active
Top Gainers
Top Losers
About
Applied DNA Sciences, Inc., a biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally. The company operates through three segments: Therapeutic DNA Production Services; MDx Testing Services; and DNA Tagging and Security Products and Services. The Therapeutic DNA Production Services segment develops and commercializes the LinearDNA platform, which enables a cell-free manufacture of high-fidelity synthetic DNA sequences for use in nucleic acid-based therapeutics. The MDx Testing Services segment provides clinical molecular diagnostics (MDx) testing and clinical laboratory testing services; COVID-19 testing services, including test scheduling, sample collection, and automated results reporting for higher education institutions, private clients, and businesses under the safeCircle trademark; polymerase chain reaction (PCR)-based MDx testing services for the Monkeypox virus; and MDx test kits and related supplies, as well as validates pharmacogenetics (PGx) testing services. The DNA Tagging and Security Products and Services segment offers SigNature Molecular Tags, which provides a methodology to authenticate goods within large and complex supply chains for materials, such as cotton, leather, pharmaceuticals, nutraceuticals, and other products; SigNify IF portable DNA readers and SigNify consumable reagent test kits, which offers a front-line solution for supply chain integrity backed with forensic-level molecular tag authentication; and fiberTyping, which uses PCR-based DNA detection to detect a product’s naturally occurring DNA sequences for the purposes of product provenance authentication and supply chain security. The company was formerly known as Datalink Systems, Inc. and changed its name to Applied DNA Sciences, Inc. in 2002. Applied DNA Sciences, Inc. was founded in 1983 and is headquartered in Stony Brook, New York.